Finally, given the characterized role of LAP in stimulating regulatory DCs, we anticipate that it will have several other important clinical applications, including the prevention or treatment of autoimmune disorders (arthritis and asthma), inflammatory bowel disease and alcohol/nonalcohol-induced chronic liver diseases. Here, TGFB1 is linked to inflammatory bowel disease.